Accéder au contenu
Merck

URG4 overexpression is correlated with cervical cancer progression and poor prognosis in patients with early-stage cervical cancer.

BMC cancer (2014-11-28)
Lan Zhang, He Huang, Longjuan Zhang, Teng Hou, Shu Wu, Qidan Huang, Libing Song, Jihong Liu
RÉSUMÉ

Upregulator of cell proliferation 4 (URG4) has been implicated in the oncogenesis of certain cancers. However, the correlation between URG4 expression and clinicopathological significance in human cancer remains unclear. Therefore, this study investigated its expression and clinicopathological significance in cervical cancer patients. URG4 expression was examined using quantitative PCR (qPCR) and western blotting in normal cervical epithelial cells, cervical cancer cells, and eight matched pairs of cervical cancer tissues and adjacent noncancerous tissues from the same patient. In addition, immunohistochemistry (IHC) was used to examine URG4 expression in paraffin-embedded tissues from 167 cervical cancer patients (FIGO stages Ib1-IIa2). Statistical analyses were performed to evaluate associations between URG4 expression and prognostic and diagnostic factors. URG4 was significantly upregulated in the cervical cancer cell lines and tissues compared with the normal cells and adjacent noncancerous cervical tissues. IHC revealed high URG4 expression in 59 out of the 167 (35.13%) cervical cancer specimens. Its expression was significantly correlated with clinical stage (P < 0.0001), tumour size (P = 0.012), T classification (P = 0.023), lymph node metastasis (P = 0.001) and vaginal involvement (P = 0.002). Patients with high URG4 expression, particularly those who received concurrent chemotherapy and radiotherapy (P < 0.0001), showed a shorter overall survival (OS) and disease-free survival (DFS) compared to those with the low expression of this protein. Multivariate analysis revealed that URG4 expression is an independent prognostic factor for cervical cancer patients. Our results demonstrated that elevated URG4 protein expression is associated with a poor outcome in patients with early-stage cervical cancer. URG4 may be a novel prognostic marker and therapeutic target for the treatment of cervical cancer.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Sodium Dodecyl Sulfate, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC)
Sigma-Aldrich
Sodium Dodecyl Sulfate, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
Sodium Dodecyl Sulfate solution, BioUltra, for molecular biology, 10% in H2O
Sigma-Aldrich
Sodium Dodecyl Sulfate solution, BioUltra, for molecular biology, 20% in H2O
Sigma-Aldrich
Sodium Dodecyl Sulfate, BioUltra, for molecular biology, ≥99.0% (GC)
Supelco
Sodium Dodecyl Sulfate, dust-free pellets, suitable for electrophoresis, for molecular biology, ≥99.0% (GC)
Sigma-Aldrich
Sodium Dodecyl Sulfate, ACS reagent, ≥99.0%
Sigma-Aldrich
Sodium Dodecyl Sulfate, ≥98.0% (GC)
Sigma-Aldrich
Sodium Dodecyl Sulfate, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
Sodium Dodecyl Sulfate, tested according to NF, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate
Sigma-Aldrich
Sodium Dodecyl Sulfate, BioXtra, ≥99.0% (GC)
Sigma-Aldrich
Sodium Dodecyl Sulfate, 92.5-100.5% based on total alkyl sulfate content basis
Supelco
Sodium Dodecyl Sulfate, suitable for ion pair chromatography, LiChropur, ≥99.0%
Sigma-Aldrich
Sodium Dodecyl Sulfate, ≥90% ((Assay))
Sodium Dodecyl Sulfate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Sodium Dodecyl Sulfate, BioReagent, suitable for electrophoresis, for molecular biology, ≥98.5% (GC), free-flowing, Redi-Dri
Sigma-Aldrich
Anti-URGCP antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, Ab1